A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Gemcitabine Plus Nab-paclitaxel (G/NP) as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Pamrevlumab (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms LAPIS
- Sponsors FibroGen
- 23 Oct 2019 According to an FibroGen media release, the first patient has been dosed in this study.
- 30 May 2019 Status changed from not yet recruiting to recruiting.
- 09 May 2019 According to a FibroGen media release, the company expects to initate this study in Q2 2019.